再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM)):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014
◆商品コード:GMDHC5797IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:248
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM))の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM))の概要
・再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM))治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM))パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM))治療薬開発に取り組んでいる企業:企業別製品パイプライン
・再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM))治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Recurrent Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2014’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Recurrent Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Recurrent Glioblastoma Multiforme (GBM) Overview 8
Therapeutics Development 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) – Overview 9
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) – Comparative Analysis 10
Recurrent Glioblastoma Multiforme (GBM) – Therapeutics under Development by Companies 11
Recurrent Glioblastoma Multiforme (GBM) – Therapeutics under Investigation by Universities/Institutes 13
Recurrent Glioblastoma Multiforme (GBM) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Recurrent Glioblastoma Multiforme (GBM) – Products under Development by Companies 17
Recurrent Glioblastoma Multiforme (GBM) – Products under Investigation by Universities/Institutes 20
Recurrent Glioblastoma Multiforme (GBM) – Companies Involved in Therapeutics Development 21
Agenus, Inc. 21
Amgen Inc. 22
AngioChem Inc. 23
Apogenix GmbH 24
AstraZeneca PLC 25
Axelar AB 26
Boehringer Ingelheim GmbH 27
Celldex Therapeutics, Inc. 28
Eisai Co., Ltd. 29
Eli Lilly and Company 30
EnGeneIC Ltd 31
ERC Belgium SA 32
Genentech, Inc. 33
GenSpera, Inc. 34
GlaxoSmithKline plc 35
GW Pharmaceuticals plc 36
ImmunoCellular Therapeutics, Ltd. 37
Karyopharm Therapeutics, Inc. 38
Novartis AG 39
OncoEthix SA 40
Ono Pharmaceutical Co., Ltd. 41
Pfizer Inc. 42
Sangamo BioSciences, Inc. 43
Spectrum Pharmaceuticals, Inc. 44
Threshold Pharmaceuticals, Inc. 45
Tocagen Inc. 46
Vascular Biogenics Ltd. 47
Virttu Biologics Limited 48
ZIOPHARM Oncology, Inc. 49
Recurrent Glioblastoma Multiforme (GBM) – Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
(GWP-42002 + GWP-42003) – Drug Profile 63
Ad-RTS-IL-12 – Drug Profile 64
afatinib – Drug Profile 66
AMG-595 – Drug Profile 70
ANG-1005 – Drug Profile 72
APG-101 – Drug Profile 74
axitinib – Drug Profile 76
AXL-1717 – Drug Profile 79
AZD-7451 – Drug Profile 81
BGJ-398 – Drug Profile 82
bosutinib – Drug Profile 83
buparlisib hydrochloride – Drug Profile 85
dacomitinib – Drug Profile 89
Dendritic Cell Therapy for Recurrent Glioblastoma Multiforme – Drug Profile 91
DNX-2401 – Drug Profile 92
dovitinib lactate – Drug Profile 94
doxorubicin – Drug Profile 97
ERC-1671 – Drug Profile 98
erismodegib – Drug Profile 100
evofosfamide – Drug Profile 103
G-200 – Drug Profile 110
galunisertib – Drug Profile 112
GDC-0084 – Drug Profile 114
golvatinib + lenvatinib – Drug Profile 115
HSV-1716 – Drug Profile 117
ICT-121 – Drug Profile 119
MDNA-55 – Drug Profile 120
mipsagargin – Drug Profile 121
nabiximols – Drug Profile 123
nivolumab (recombinant) – Drug Profile 126
Oncolytic Virus to Target IL-12 for Oncology – Drug Profile 131
ortataxel – Drug Profile 132
OS-2966 – Drug Profile 133
OTX-015 – Drug Profile 134
pazopanib hydrochloride – Drug Profile 136
rilotumumab – Drug Profile 141
rindopepimut – Drug Profile 143
SB-313 – Drug Profile 145
selinexor – Drug Profile 146
TPI-287 – Drug Profile 149
trebananib – Drug Profile 151
Vaccine to Target Carcinoembryonic Antigen for Oncology – Drug Profile 154
vandetanib – Drug Profile 155
VB-111 – Drug Profile 161
vocimagene amiretrorepvec + flucytosine ER – Drug Profile 162
Recurrent Glioblastoma Multiforme (GBM) – Recent Pipeline Updates 164
Recurrent Glioblastoma Multiforme (GBM) – Dormant Projects 235
Recurrent Glioblastoma Multiforme (GBM) – Discontinued Products 236
Recurrent Glioblastoma Multiforme (GBM) – Product Development Milestones 237
Featured News & Press Releases 237
Appendix 244
Methodology 244
Coverage 244
Secondary Research 244
Primary Research 244
Expert Panel Validation 244
Contact Us 245
Disclaimer 245

[List of Tables]
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2014 12
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Products under Development by Companies, H2 2014 (Contd..2) 22
Products under Investigation by Universities/Institutes, H2 2014 23
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2014 24
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2014 25
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2014 26
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2014 27
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca PLC, H2 2014 28
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2014 29
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 30
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H2 2014 31
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2014 32
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2014 33
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2014 34
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2014 35
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H2 2014 36
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H2 2014 37
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline plc, H2 2014 38
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals plc, H2 2014 39
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 40
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 41
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2014 42
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by OncoEthix SA, H2 2014 43
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 44
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2014 45
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Sangamo BioSciences, Inc., H2 2014 46
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 47
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 48
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2014 49
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2014 50
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2014 51
Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 52
Assessment by Monotherapy Products, H2 2014 53
Assessment by Combination Products, H2 2014 54
Number of Products by Stage and Target, H2 2014 56
Number of Products by Stage and Mechanism of Action, H2 2014 60
Number of Products by Stage and Route of Administration, H2 2014 63
Number of Products by Stage and Molecule Type, H2 2014 65
Recurrent Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H2 2014 167
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2014 238
Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2014 239

[List of Figures]
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2014 12
Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 18
Assessment by Monotherapy Products, H2 2014 53
Number of Products by Top 10 Targets, H2 2014 55
Number of Products by Stage and Top 10 Targets, H2 2014 55
Number of Products by Top 10 Mechanism of Actions, H2 2014 59
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 59
Number of Products by Top 10 Routes of Administration, H2 2014 62
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 63
Number of Products by Top 10 Molecule Types, H2 2014 64
Number of Products by Stage and Top 10 Molecule Types, H2 2014 65

【掲載企業】

Agenus, Inc.
Amgen Inc.
AngioChem Inc.
Apogenix GmbH
AstraZeneca PLC
Axelar AB
Boehringer Ingelheim GmbH
Celldex Therapeutics, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
Genentech, Inc.
GenSpera, Inc.
GlaxoSmithKline plc
GW Pharmaceuticals plc
ImmunoCellular Therapeutics, Ltd.
Karyopharm Therapeutics, Inc.
Novartis AG
OncoEthix SA
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Sangamo BioSciences, Inc.
Spectrum Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
Vascular Biogenics Ltd.
Virttu Biologics Limited
ZIOPHARM Oncology, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[再発性多形性膠芽腫(Recurrent Glioblastoma Multiforme (GBM)):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆